Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Simple item page
dc.contributor.authorØrnbjerg L.M.
dc.contributor.authorLinde L.
dc.contributor.authorGeorgiadis S.
dc.contributor.authorRasmussen S.H.
dc.contributor.authorLindström U.
dc.contributor.authorAskling J.
dc.contributor.authorMichelsen B.
dc.contributor.authorGiuseppe D.D.
dc.contributor.authorWallman J.K.
dc.contributor.authorPavelka K.
dc.contributor.authorZávada J.
dc.contributor.authorNissen M.J.
dc.contributor.authorJones G.T.
dc.contributor.authorRelas H.
dc.contributor.authorPirilä L.
dc.contributor.authorTomšič M.
dc.contributor.authorRotar Z.
dc.contributor.authorGeirsson A.J.
dc.contributor.authorGudbjornsson B.
dc.contributor.authorKristianslund E.K.
dc.contributor.authorvan sder Horst-Bruinsma I.
dc.contributor.authorLoft A.G.
dc.contributor.authorLaas K.
dc.contributor.authorIannone F.
dc.contributor.authorCorrado A.
dc.contributor.authorCiurea A.
dc.contributor.authorSantos M.J.
dc.contributor.authorSantos H.
dc.contributor.authorCodreanu C.
dc.contributor.authorAkkoc N.
dc.contributor.authorGunduz O.S.
dc.contributor.authorGlintborg B.
dc.contributor.authorØstergaard M.
dc.contributor.authorHetland M.L.
dc.date.accessioned2024-07-22T08:03:59Z
dc.date.available2024-07-22T08:03:59Z
dc.date.issued2022
dc.description.abstractObjectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97–0.98), men vs. women: 1.88 (1.60–2.22), current vs. non-smoking: 0.76 (0.63–0.91), HLA-B27 positive vs. negative: 1.51 (1.20–1.91), TNF start year 2015–2018 vs. 2009–2014: 1.24 (1.06–1.45), CRP>10 vs. ≤10 mg/l: 1.49 (1.25–1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58–1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99–1.00) and 0.99 (0.99–1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations. © 2022
dc.identifier.DOI-ID10.1016/j.semarthrit.2022.152081
dc.identifier.issn00490172
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12523
dc.language.isoEnglish
dc.publisherW.B. Saunders
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectadalimumab
dc.subjectC reactive protein
dc.subjectcertolizumab pegol
dc.subjectetanercept
dc.subjectgolimumab
dc.subjectinfliximab
dc.subjecttumor necrosis factor inhibitor
dc.subjectadult
dc.subjectage distribution
dc.subjectAnkylosing Spondylitis Disease Activity Score
dc.subjectArticle
dc.subjectaxial spondyloarthritis
dc.subjectBath ankylosing spondylitis disease activity index
dc.subjectclinical feature
dc.subjectclinically important improvement
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectcurrent smoker
dc.subjectdemographics
dc.subjectdisease activity
dc.subjectdisease registry
dc.subjectEurope
dc.subjectfatigue
dc.subjectfemale
dc.subjectHealth Assessment Questionnaire
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedication compliance
dc.subjectnon-smoker
dc.subjectpatient compliance
dc.subjectsex difference
dc.subjectspinal pain
dc.subjecttreatment duration
dc.subjecttreatment response
dc.titlePredictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
dc.typeArticle

Files

Collections

Scopus Koleksiyonu